Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1

Abstract

The invention relates to compounds of formula I:wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to LFA-1 integrin antagonists to target cells expressing LFA-1.

Description

PRIORITY TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Patent Application No. 61 / 678,673, filed Aug. 2, 2012, and U.S. Provisional Patent Application No. 61 / 591,297, filed Jan. 27, 2012, the disclosures of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to the synthesis and reaction of potent and selective small molecule integrin antagonists containing appropriate linkers and functional groups for chemical reaction with other molecules which contain reactive nucleophiles such as thiols such that a covalent linkage is formed between a moiety to be conjugated and the targeting entity. The small molecule targeting antagonists bind to cognate receptor systems as LFA-1 antagonists and / or dual LFA-1 / MAC-1 antagonists to the ICAM-1 receptor. The covalently linked moiety includes small molecule therapeutics, polymers, peptides, and oligonucleotides. Included are 5′-thio-containing o...

AI Technical Summary

Benefits of technology

This patent is about a group of compounds (Formula I) that can deliver various molecules to specific cells in the body. These compounds can be used for therapeutic purposes and are able to target specific types of cells that are associated with inflammation and autoimmune diseases. The patent also describes methods for making and using these compounds.

Problems solved by technology

One of the problems in using nucleic acids such as siRNA in therapeutic applications (especially for systemic administration in humans) has been in delivering the nucleic acids to: (1) particular target tissues or cell types and (2) to the cytoplasm of those cells (i.e., where the mRNA is present and translated into protein).

Part of the delivery problem is based on the fact that nucleic acids are negatively charged and easily degraded (especially if unmodified), efficiently filtered by the kidney, and cannot be easily transported to the cytoplasm of the cells by themselves.

Images